Fig. 3.

Regulation of DME and transporter mRNA levels in TCPOBOP-pretreated mice following LTA administration. CAR^+/+ mice were treated with the specific CAR activator, TCPOBOP (3 mg/kg/d), for 3 days prior to i.p. administration of saline or LTA (6 mg/kg). Livers were harvested after (A) 4 hours and (B) 16 hours, and mRNA levels were analyzed by real-time PCR, as described earlier. All data are presented as ±S.D. and standardized for cyclophilin mRNA levels. Expression in saline-treated mice was set to 1; fold change after LTA treatment was compared with the saline-treated controls. *Indicates significant difference (P < 0.05) between saline and LTA groups, and # indicates significant differences between saline samples of −TCPOBOP (−TC) and +TC groups. The experiments were repeated at least thrice. (C) Cytosolic and nuclear extracts were prepared from livers from CAR^+/+ mice treated with TCPOBOP (3 mg/kg/d) for 3 days prior to saline and LTA (6 mg/kg) i.p. injections (4 hours), and CAR protein levels were measured by Western blotting. (D) The images were quantified by densitometer using AlphaEase software. The normalized values of fold difference, relative to the expression of LDH for cytosolic extracts and lamin A/C for nuclear extracts, which was set to 1, are presented as mean ± S.D. values. (E) Regulation of CAR mRNA levels by LTA in TCPOBOP-pretreated mice. C57BL/6 mice were pretreated for 3 days with 3 mg/kg TCPOBOP (i.p.) in corn oil prior to treatment with saline or LTA (6 mg/kg), and livers were harvested at 2 hours (n = 5 per group). All data are presented as ±S.D. and standardized for cyclophilin mRNA levels. Expression in TCPOBOP/saline-treated mice was set to 1; fold change after LTA treatment was compared with the saline-treated controls.